BioMarin Pharmaceutical, Inc. (BMRN)
59.43
+0.44
(+0.75%)
USD |
NASDAQ |
Dec 31, 16:00
59.45
+0.02
(+0.03%)
Pre-Market: 20:00
BioMarin Pharmaceutical Research and Development Expense (TTM): 682.06M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amicus Therapeutics, Inc. | 142.29M |
| Gilead Sciences, Inc. | 5.734B |
| Merck & Co., Inc. | 14.26B |
| AbbVie, Inc. | 8.815B |
| Bristol Myers Squibb Co. | 9.719B |